{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"10.9","value":"18.0"},{"groupId":"OG001","spread":"11.5","value":"16.5"}]}],"title":"Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"9.7","value":"9.4"},{"groupId":"OG001","spread":"13.7","value":"19.7"}]}],"title":"Week 24"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"10.0","value":"-8.6"},{"groupId":"OG001","spread":"9.4","value":"3.2"}]}],"title":"Change from Baseline"}],"denoms":[{"counts":[{"groupId":"OG000","value":"131"},{"groupId":"OG001","value":"105"}],"units":"Participants"}],"description":"Symptoms of myelofibrosis were assessed using a modified Myelofibrosis Symptom Assessment Form (MFSAF) Version 2.0 diary. Using the diary, patients rated the following symptoms on a scale from 0 (absent) to 10 (worst imaginable): night sweats, itching, abdominal discomfort, pain under ribs on left, feeling of fullness (early satiety), and muscle/bone pain. The total symptom score ranged from 0-60 and was calculated as the sum of the 6 symptom scores. A higher score indicates worse symptoms hence a negative change from baseline indicates improvement.","dispersionType":"Standard Deviation","groups":[{"description":"Participants began treatment with ruxolitinib 15 or 20 mg taken orally twice a day based on Baseline platelet count. The dose was adjusted by the Investigator based on efficacy and safety to a maximum of 25 mg twice daily.","id":"OG000","title":"Ruxolitinib"},{"description":"Placebo tablets matching ruxolitinib were administered orally twice a day at a starting dose based on Baseline platelet count. Doses were titrated using the same guidelines as for active drug. Patients meeting pre-specified requirements were given the opportunity to cross over to ruxolitinib treatment.","id":"OG001","title":"Placebo"}],"paramType":"MEAN","populationDescription":"This analysis only includes patients who had a non-missing change from Baseline to Week 24. Data collected after the date of treatment cross over were not included in this analysis.","reportingStatus":"POSTED","timeFrame":"Baseline and Week 24. Baseline total score was the average of the daily total scores for the last 7 days prior to randomization. The Week 24 total score was the average of daily total scores from the 28 days prior to the Week 24 visit.","title":"Change From Baseline to Week 24 in Total Symptom Score","type":"SECONDARY","unitOfMeasure":"scores on a scale"}